Eli Lilly’s new GLP-1 drug and diversified R&D pipeline could drive healthcare sector inflows and deliver over 40% upside. See here for more on LLY stock.
Unsustainable AI-driven capex by big tech may threaten profitability and distort valuations. Read the latest analysis on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback